Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is the first multiple-dose study in humans with PRA-027. This study will provide an
assessment of the safety, tolerability, pharmacokinetics (how the drug is absorbed,
metabolized and excreted by the body) and pharmacodynamics (a measure of whether the drug is
active in the body) of PRA-027 after administration of 28 days of oral doses in women of
childbearing potential (cycling) or postmenopausal women.